The current issues in Hypoglycaemia

Prof. Brian Frier speak about the latest findings on the treatment of the disease.

Current guidelines on diabetes management

Prof. Christoph Wanner speaks about the latest guidelines and findings on treatment and comprehensive care for diabetes.

Accumulated CV data from SGLT2i outcomes trials

The dawn of CV risk reduction in type 2 diabetes: 5 years of SGLT2i CV outcome trials.

Summary of clinical and scientific topics discussed at EASD 2020 congress

The most important clinical and scientific findigs presented at the EASD 2020 Virtual Congress are summed up by Professor Stefano Del Prato.

Remission of type 2 diabetes with return of insulin secretory function restores normal pancreas morphology

The size and shape of the pancreas can be restored in individuals with type 2 diabetes who achieve remission as a result of an intensive weight loss and weight loss maintenance programme, shows a new analysis from the landmark DiRECT trial.

Effects of empagliflozin on physical activity and compensatory appetite responses in people with type 2 diabetes: the SEESAW trial

https://www.easd.org/virtualmeeting/home.html#!resources/effects-of-empagliflozin-diet-or-both-on-physical-activity-and-sedentary-behaviour-in-people-with-type-2-diabetes-analyses-from-the-seesaw-trial-33e5cd8a-0212-4173-ab31-02bd789ec795

Highlights of the 2019 EASD Congress

David R. Matthews, President of EASD explains the EASD statement on the new guidelines and summarize the highlights of the congress.

DAPA HF : The Dapagliflozin And Prevention Of Adverse‑ outcomes In Heart Failure Trial

The aims of this study were to: (i) report the baseline characteristics of patients enrolled in the Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial, (ii) compare DAPA-HF patients to participants in contemporary heart failure (HF) registries and in other recent HF trials, and (iii) compare individuals with diabetes, pre-diabetes and a normal glycated haemoglobin (HbA1c) in DAPA-HF.

Early intervention with oral semaglutide and long term safety

Prof. Melanie Davies speaks about the two torchbearers in cardiovascular protection in diabetes, the SGLT2 inhibitors and GLP-1 analogs.

VERIFY and CONCLUDE study

Prof. Stefano Del Prato summarize the new findings of the VERIFY and CONCLUDE studies.

Cardiorenal risk in type 2 diabetes

Prof. Tina Vilsbøll discusses the current opinion about cardiorenal risk in patients with T2D.

Clinical properties and differences between GLP-1 agonists

Michael A. Nauck speaks about on the combinations of DPP4 inhibitors and SGLT2 inhibitors.

Why We Should Still Care about Glycemic Lowering Strategies for Type 2 Diabetes

Prof. Hertzel Gerstein speaks about the question of the importance of glycemic control in the management of type 2 diabetes.

Diabetic retinopathy: Is the eye a mirror of the brain?

Prof. Coen D. A. Stehouwer speaks about the connection between diabetic retinopathy and other complications of diabetes.

Cardiovascular mode of action of GLP-1 receptor agonists

Exploring the effects of SGLT2 inhibition in ongoing clinical trials

Medical Devices in Diabetes

Will SGLT2-inhibitors change the landscape?

Innate immunity in pancreatic islet inflammation

The artificial beta cell. When will the dream become reality?

Observational study of insulin pump treatment

The evidence for metformin is unclear?

The ORIGIN Study And Legacy Effects

EMPA-REG OUTCOME - a long-term, outcom study of empagliflozin in pateints with T2D at high CV risk

Principal investigator presenting the results of EMPA-REG OUTCOME trial

Joint Statement on Diabetes Self-Management Education

Joint Statement on Diabetes Self-Management Education

Joint Statement on Diabetes Self-Management Education

50 years of clinical research in diabetes

50 years in treatment of diabetes complications

50 years of diabetes treatment

75 years with diabetes – a patient’s perspective